Skip to main content

Table 3 Toxicity in patients treated with nab-paclitaxel (N = 31)

From: A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer

Toxicity

Grade1/2

%

Grade3

%

Grade 4

%

Grade3/4

%

Leukopenia

21

67.7

6

19.3

1

3.2

7

22.5

Neutropenia

17

54.8

6

19.3

6

19.3

12

38.6

Anemia

25

80.6

1

3.2

0

0

1

3.2

Thrombocytopenia

5

16.1

0

0

0

0

0

0

Febrile neutropenia

 

4

12.9

Nausea/vomiting

5

16.1

2

6.4

0

0

2

6.4

Anorexia

10

32.2

1

3.2

0

0

1

3.2

Infection

7

22.5

3

9.6

1

3.2

4

12.9

Neuropathy

19

61.2

3

9.6

0

0

3

9.6

Fatigue

22

70.9

0

0

0

0

0

0

Liver dysfunction

10

32.2

1

3.2

0

0

1

3.2

Diarrhea

6

19.3

0

0

0

0

0

0

Hyperkalemia

7

22.5

0

0

0

0

0

0

Edema

0

0

1

3.2

0

0

0

0